Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its
novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™
(nsPFA™) technology, today announced CellFX nsPFA technology will
be featured in multiple presentations at the upcoming Heart Rhythm
Society (HRS) 2024 Annual Meeting in Boston, MA from May 16-19.
“We look forward to our proprietary CellFX nsPFA technology
being highlighted in six total presentations and abstracts, and in
a live case presentation at the prestigious HRS meeting,” said
Darrin Uecker, Chief Technology Officer and Director of Pulse
Biosciences. “The preclinical and initial clinical outcomes from
studies with our surgical clamp and catheter are encouraging and we
continue to believe that CellFX nsPFA can meaningfully advance the
treatment of atrial fibrillation.”
“Our innovative energy delivery platform technology allows us to
uniquely meet the needs of both cardiac surgeons and EPs who
together treat all types of patients with cardiac ailments,” added
President and Chief Executive Officer Burke T. Barrett. “I am
looking forward to speaking with, now as part of Pulse Biosciences,
the many providers in the clinical community I have met over the
years.”
CellFX nsPFA technology will be featured
at the following times at the HRS 2024 Annual Meeting:
Thursday, May 16, 2024
PFA Live Case Summit
Time:
1:30pm to 3:00pm ET
Location:
Boston Convention & Exhibition Center, Room 210BC
Session III - Live/Recorded PFA Cases
Live Case: PVI+ with Nanosecond PFA (CellFX® nsPFA™; Pulse
Biosciences)
Live Case Site: Na Homolce Hospital
Live Case Operators: Jan Petru, MD, and Moritoshi Funasako, MD, PhD
Friday, May 17, 2024
Presentation | Understanding
Novel Ablation Technologies: Insights from Biophysics and
Preclinical Studies
Time:
1:25pm to 1:30pm ET
Location:
Moderated Poster Hub 3 - BCEC
Nanosecond Pulsed Field Myocardial Ablation: Preclinical
Evaluation using a Novel Catheter and Generator (MP-483493-002)
Keita Watanabe, MD (presenting author), Moritz Nies, MD, Abhishek
Mann, William Whang, MD, Srinivas R. Dukkipati, MD, Vivek Y. Reddy,
MD, Jacob S. Koruth, MD
Saturday, May 18, 2024
Presentation | Poster Session
V - Ablation
Time:
1:30pm – 3:30pm ET
Location:
Abstract Pavilion - BCEC
First-in-Human Clinical Experience of Pulse Field Ablation Using
Nanosecond Pulses to Treat Atrial Fibrillation (PO-05-158)
Vivek Y. Reddy, MD (presenting author), Jacob S. Koruth, MD, Jan
Petru, MD, Moritoshi Funasako, MD, PhD, Pavel Hala, MD, Jan Skoda,
MD, Petr Neuzil, MD, PhD
Sunday, May 19, 2024
Presentation | Poster Session
VI - Ablation
Time:
9:30am to 11:30am ET
Location:
Abstract Pavilion - BCEC
Focal Nanosecond Pulsed Field Ablation: Preclinical Assessment
of a Novel Catheter Tip Design (PO-06-142)
Keita Watanabe, MD (presenting author), Moritz Nies, MD, Srinivas
R. Dukkipati, MD, Marc A. Miller, MD, William Whang, MD, Joshua
Lampert, MD, Vivek Y. Reddy, MD, Jacob S. Koruth, MD
Exploring Esophageal Effects After Pulsed Field Ablation:
Preclinical Evaluation of Nanosecond Pulse using a Dedicated
Endocardial System (PO-06-151)
Jacob S. Koruth, MD (presenting author), Moritz Nies, MD, Keita
Watanabe, MD, Daniel Musikantow, Mohit Turagam, Joshua Lampert, MD,
Marc A. Miller, MD, Vivek Y. Reddy, MD
Performance of the First Bipolar Nanosecond Pulsed Field
Ablation (nsPFA) Clamp in a Chronic Porcine Model (PO-06-152)
Gansevoort Hurlbut Dunnington, MD (presenting author), Swami
Gnanashanmugam, David Danitz, MSME, Lauren Johnston, Darrin Uecker,
MSEE, Jeffrey Litt, Anita Crompton, Mike Smith, Ilya Getsin, Niv
Ad, MD
Ultrafast Delivery of Consistent Endocardial and Epicardial
Transmural Ablation Lesions Using a New Nanosecond Pulsed Field
Ablation (nsPFA) Platform (PO-06-153)
Gansevoort Hurlbut Dunnington, MD (presenting author), Chad Brodt,
Swami Gnanashanmugam, David Danitz, MSME, Lauren Johnston, Darrin
Uecker, MSEE, Jeffrey Litt, Anita Crompton, Roman Turovskiy, Ilya
Getsin, Niv Ad, MD
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company
committed to health innovation that has the potential to improve
the quality of life for patients. The Company’s proprietary CellFX®
nsPFA™ technology delivers nanosecond pulses of electrical energy
to non-thermally clear cells while sparing adjacent noncellular
tissue. The Company is actively pursuing the development of its
CellFX nsPFA technology for use in the treatment of atrial
fibrillation and in a select few other markets where it could have
a profound positive impact on healthcare for both patients and
providers.
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA,
CellFX nsPFA and the stylized logos are among the trademarks and/or
registered trademarks of Pulse Biosciences, Inc. in the United
States and other countries.
Forward-Looking Statements
All statements in this press release that are not historical are
forward-looking statements, including, among other things,
statements relating to the potential effectiveness and uniqueness
of the Company’s CellFX nsPFA technology to treat cardiac ailments,
statements concerning pre-clinical or early clinical successes and
whether they are predictive of the safety and efficacy of any
medical device, and the Company’s expectations, whether stated or
implied, regarding whether the Company’s CellFX nsPFA technology
will become a disruptive and durable treatment option for treating
any medical condition, and other future events. These statements
are not historical facts but rather are based on Pulse Biosciences’
current expectations, estimates, and projections regarding Pulse
Biosciences’ business, operations and other similar or related
factors. Words such as “may,” “will,” “could,” “would,” “should,”
“anticipate,” “predict,” “potential,” “continue,” “expects,”
“intends,” “plans,” “projects,” “believes,” “estimates,” and other
similar or related expressions are used to identify these
forward-looking statements, although not all forward-looking
statements contain these words. You should not place undue reliance
on forward-looking statements because they involve known and
unknown risks, uncertainties, and assumptions that are difficult or
impossible to predict and, in some cases, beyond Pulse Biosciences’
control. Actual results may differ materially from those in the
forward-looking statements as a result of a number of factors,
including those described in Pulse Biosciences’ filings with the
Securities and Exchange Commission. Pulse Biosciences undertakes no
obligation to revise or update information in this release to
reflect events or circumstances in the future, even if new
information becomes available.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240516957050/en/
Investor Contacts: Pulse Biosciences, Inc. Burke T.
Barrett, President and CEO IR@pulsebiosciences.com
Or
Gilmartin Group Philip Trip Taylor 415.937.5406
philip@gilmartinir.com
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From May 2024 to Jun 2024
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Jun 2023 to Jun 2024